Adding bortezomib (Velcade) to standard preventive therapy for graft-versus-host-disease results in improved outcomes for patients receiving stem-cell transplants from mismatched and unrelated donors, according to researchers from Dana-Farber Cancer Institute.
Fuente : http://www.eurekalert.org/pub_releases/2013-12/dci...
Fuente : http://www.eurekalert.org/pub_releases/2013-12/dci...